Head of European Market Access – Oncology (Solid Tumors)

The role

The Head of European Market Access – Oncology (Solid Tumors) will drive pricing, reimbursement, health technology assessment, and patient access strategies for the oncology portfolio across Europe. This leader will shape European commercialization strategies and ensure optimal market access for innovative therapies.

What you will do

• Develop and execute an integrated European market access strategy for oncology products.
• Lead access planning across the EU5 and other strategically important markets.
• Translate global pricing and access objectives into country-specific strategies.
• Identify market access opportunities, barriers, and risks in clinical development.
• Serve as the European market access subject matter expert to senior leadership.
• Lead development of pricing and reimbursement strategies including launch sequencing and lifecycle management.
• Develop country-specific HTA strategies and reimbursement submissions.
• Partner with Global Clinical Development, Medical Affairs, Regulatory Affairs, and HEOR teams.
• Lead market access launch readiness activities.
• Establish and maintain relationships with national and regional payers and HTA experts.

Required qualifications

• Advanced degree in life sciences, pharmacy, medicine, health economics, public health, business, or a related discipline.
• Minimum of 15+ years of pharmaceutical or biotechnology industry experience, with significant responsibility for European market access, pricing, reimbursement, or HTA.
• At least 5+ years of substantial oncology market access experience.
• Demonstrated experience in NSCLC, colorectal cancer, and/or bladder/urothelial cancer.
• Proven track record of developing and executing successful European pricing and reimbursement strategies for innovative oncology products.
• Strong knowledge of the EU5 healthcare systems, HTA processes, reimbursement pathways, and payer decision-making.
• Understanding of the evolving US MFN and Global pricing and reimbursement along with impact of international reference pricing and sequence.
• Direct experience supporting European oncology launches, HTA submissions, and national pricing or reimbursement negotiations.
• Ability to translate complex clinical and health economic evidence into compelling payer value propositions.
• Strong understanding of oncology clinical trial design, endpoints, treatment guidelines, and competitive positioning.
• Experience working in global and regional matrix organizations and influencing cross-functional stakeholders.
• Fluent English required.

Nice to have

• MBA, PharmD, PhD, or MD
• Experience launching novel oncology therapies, including immunotherapies, targeted therapies, or antibody-drug conjugates.
• Experience with European reimbursement of oncology combination therapies and biomarker-selected patient populations.
• Prior responsibility for European market access strategy across multiple oncology indications.
• Experience with biotechnology companies transitioning from clinical development to commercialization.
• Demonstrated ability to develop market access strategies for first-in-class and best-in-class therapies.
• Experience with European pricing strategy, gross-to-net forecasting, confidential rebates, and managed entry agreements.
• Experience assessing European commercial opportunities for business development transactions or licensing partnerships.
• Familiarity with EU joint clinical assessment requirements and evolving European pharmaceutical policy.
• Established professional relationships within European oncology payer and HTA networks.

Benefits

• Bonus
• Stock
• Benefits
• Other applicable variable compensation

About the company

Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs.